晟德投控以「藥業」起家，擁有豐富的生技實務與商業專業，瞭解產業價值鏈與生態，並具備強大的專家網絡及資源整合能力。我們的主要投資策略如下：
1. 聚焦選題：我們將持續發揮在醫療及大健康領域的優勢，結合創新科技及趨勢，掌握未來的商機；同時，我們將往上下游拓展，擴大規模經濟，並涵蓋製造、渠道及服務等層面。
2. 資產循環：我們持續優化投資組合、擴大投資效益，並協助轉投資企業調整策略。在追求企業高度成長時，我們努力在創新、穩健及高流通性間取得平衡。
3. 資源整合：我們將轉投資企業以集團化經營，整合國際資源，並共享經驗、知識及人材。
Center Ventures started with pharmaceutical business in 1957. Now we are the most professional biotech corporate venture capital (CVC) in Taiwan, with nearly 1B USD in AUM. Our main investment strategy is as follows:
1. Focus on selection: We will continue to leverage our advantages in the medical and health fields, combine innovative technology and trends, and seize future opportunities; at the same time, we will expand upstream and downstream, increase economies of scale, and cover manufacturing, channels and services.
2. Asset management: We continue to optimize our investment portfolio, expand our investment benefits, and assist our invested companies in adjusting their strategies. While pursuing high growth of enterprises, we strive to achieve a balance between innovation, stability and high liquidity.
3. Resource integration: We will operate our invested companies in a group manner, integrate international resources, and share experience, knowledge and talent.
Company Details
- Employees
- 47
- Founded
- -
- Address
- 南港區園區街3-2號7樓, 南港軟體園區h棟,taiwan, Province Of China
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- centerlab.com.tw
- HQ
- 台北市
晟德（two：4123）center Ventures Questions
晟德（Two：4123）Center Ventures's website is centerlab.com.tw
晟德（Two：4123）Center Ventures's LinkedIn profile is https://tw.linkedin.com/company/center-ventures
晟德（Two：4123）Center Ventures has
47 employees.
View email and phone details for 47
employees at 晟德（Two：4123）Center Ventures.
晟德（Two：4123）Center Ventures's industry is
Venture Capital and Private Equity Principals
晟德（Two：4123）Center Ventures's top competitors are
Eirgenix, Inc.,
Bora Pharmaceuticals,
Development Center For Biotechnology,
Anya Biopharm Inc.,
Acer Medical,
Lumosa Therapeutics Co., Ltd.,
Krisan Biotech Co., Ltd.,
Obi Pharma,
Merck Group,
Mycenax Biotech Inc..
晟德（Two：4123）Center Ventures's categories are Venture Capital and Private Equity Principals
晟德（Two：4123）Center Ventures's founding year is 1957
